B1N0 Stock Overview
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Bionomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$4.30 |
| 52 Week Low | US$0.31 |
| Beta | -0.12 |
| 11 Month Change | 23.04% |
| 3 Month Change | -8.74% |
| 1 Year Change | -84.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1N0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -27.7% | 2.6% | 4.5% |
| 1Y | -84.3% | -16.4% | 13.4% |
Return vs Industry: B1N0 underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: B1N0 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| B1N0 volatility | |
|---|---|
| B1N0 Average Weekly Movement | 40.6% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B1N0's share price has been volatile over the past 3 months.
Volatility Over Time: B1N0's weekly volatility (41%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited Fundamentals Summary
| B1N0 fundamental statistics | |
|---|---|
| Market cap | €7.59m |
| Earnings (TTM) | -€19.18m |
| Revenue (TTM) | €409.41k |
18.5x
P/S Ratio-0.4x
P/E RatioIs B1N0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1N0 income statement (TTM) | |
|---|---|
| Revenue | AU$661.98k |
| Cost of Revenue | AU$16.58m |
| Gross Profit | -AU$15.92m |
| Other Expenses | AU$15.09m |
| Earnings | -AU$31.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.34 |
| Gross Margin | -2,405.04% |
| Net Profit Margin | -4,684.05% |
| Debt/Equity Ratio | 3.9% |
How did B1N0 perform over the long term?
See historical performance and comparison